- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04359108
Environmental Localization Mapping and Guidance for Visual Prosthesis Users (SLAM)
Study Overview
Status
Intervention / Treatment
Detailed Description
About 1.3 million Americans aged 40 and older are legally blind, a majority because of diseases with onset later in life, such as glaucoma and age-related macular degeneration. Second Sight Medical Products (SSMP) has developed the world's first FDA approved retinal implant, Argus II, intended to restore some functional vision for people suffering from retinitis pigmentosa (RP). In this era of smart devices, generic navigation technology, such as GPS mapping apps for smartphones, can provide directions to help guide a blind user from point A to point B. However, these navigational aids do little to enable blind users to form an egocentric understanding of the surroundings, are not suited to navigation indoors, and do nothing to assist in avoiding obstacles to mobility. The Argus II, on the other hand, provides blind users with a limited visual representation of their surroundings that improves users' ability to orient themselves and traverse obstacles, yet lacks features for high-level navigation and semantic interpretation of the surroundings. The proposed study aims to address these limitations of the Argus II through a synergy of state-of-the-art simultaneous localization and mapping (SLAM) and object recognition technologies.
This study is driven by the hypothesis that navigation for users of retinal prosthetics can be greatly improved by incorporating SLAM and object recognition technology conveying environmental information via a retinal prosthesis and auditory feedback. SLAM enables the visual prosthesis system to construct a map of the user's environment and locate the user within that map. The system then provides object location and navigational cues via appropriate sensory modalities enabling the user to mentally form an egocentric map of the environment. Investigators will develop and test a visual prosthesis system which 1) constructs a map of unfamiliar environments and localizes the user using SLAM technology 2) automatically identifies navigationally-relevant objects and landmarks using object recognition and 3) provides sensory feedback for navigation, obstacle avoidance, and object/landmark identification.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Seth Billings, Ph.D.
- Phone Number: 4437787462
- Email: seth.billings@jhuapl.edu
Study Contact Backup
- Name: Francesco Tenore, Ph.D.
- Phone Number: 4437789774
- Email: francesco.tenore@jhuapl.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Recruiting
- Johns Hopkins Medicine - Wilmer Eye Institute
-
Contact:
- Gislin Dagnelie, PhD
- Phone Number: 410-614-4822
- Email: gislin@lions.med.jhu.edu
-
Principal Investigator:
- Gislin Dagnelie, PhD
-
Laurel, Maryland, United States, 20723
- Recruiting
- Johns Hopkins Applied Physics Laboratory
-
Contact:
- Seth Billings, Ph.D.
- Phone Number: 443-778-7462
- Email: seth.billings@jhuapl.edu
-
Principal Investigator:
- Seth Billings, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Criteria for inclusion of normally sighted individuals:
- Subject speaks English;
- Subjects must be an adult (at least 18 years of age);
- Subject has the cognitive and communication ability to participate in the study (i.e., follow spoken directions, perform tests, and give feedback);
- Subject is willing to conduct psychophysics testing up to 4-6 hours per day of testing on 3-5 consecutive days;
- Subject has visual acuity of 20/40 or better (corrected);
- Subject is capable of understanding participant information materials and giving written informed consent.
- Subject is able to walk unassisted
Criteria for inclusion of Argus II users:
The inclusion criteria for the study are the following:
- Subject is at least 25 years of age;
- Subject has been implanted with the Argus II system;
- Subject's eye has healed from surgery and the surgeon has cleared the subject for programming;
- Subject has the cognitive and communication ability to participate in the study (i.e., follow spoken directions, perform tests, and give feedback);
- Subject is willing to conduct psychophysics testing up to 4-6 hours per day of testing on 3-5 consecutive days;
- Subject is capable of understanding patient information materials and giving written informed consent;
- Subject is able to walk unassisted.
Exclusion criteria for all subjects is the following:
- Subject is unwilling or unable to travel to testing facility for at least 3 days of testing within a one-week timeframe;
- Subject does not speak English;
- Subject has language or hearing impairment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Navigation system for users of a visual prosthesis
This intervention will assess the feasibility of using a navigation system to aid blind users of a visual prosthesis with navigation tasks, by using the navigation system to provide navigational cues through multiple sensory modalities including vision and audition.
The navigation system will be designed and developed as part of the proposed research and will interface with the Argus II retinal prosthesis system, which is an FDA approved visual prosthesis.
Existing blind users of the Argus II device will be recruited for this study, and the navigation system will interface with these subjects' existing Argus II systems.
Sighted subjects will also be recruited for this study, in which case the navigation system will interface with a head-mounted display (such as the Oculus Rift) worn by the sighted subjects that simulates the visual sensory information experienced by blind users of the Argus II retinal implant.
|
We use common psychophysical judgments such as the following: discriminating between two alternatives by saying which is present in the field of view, touching a tablet computer to indicate the apparent location of a target in the frontal plane, and looking for targets by rotating the head and pointing when one is found.
We will compare user performance using the Basic system with user performance using the Augmented and Augmented + Modal systems where contextual information associated with the task is conveyed to users via enhanced visual, auditory, and haptic modalities.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Accuracy as assessed as ratio of target identification success to total trials
Time Frame: Up to 5 minutes
|
The participant will be asked to identify intended targets in a closed environment, as well as to navigate to intended targets.
We will measure accuracy as the total number of successes divided by the total number of trials.
|
Up to 5 minutes
|
Trial Time as assessed by mean time duration to identify target
Time Frame: Up to 5 minutes
|
This will be assessed by the mean duration of time to identify intended target (in seconds).
For successful trials, the shorter the amount of time to conduct a task, the better the performance on said task.
|
Up to 5 minutes
|
Success in psychophysical judgments
Time Frame: Trial Duration: estimated at up to one minute.
|
This will be assessed by the metric error in distance judgment, that is, the correctness of identification of judgments of target features.
Measurement in meters.
|
Trial Duration: estimated at up to one minute.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Seth Billings, Ph.D., Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00228932
- 1R01EY029741-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinitis Pigmentosa
-
MeiraGTx UK II LtdSyne Qua Non Limited; Bionical EmasCompletedGene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)X-Linked Retinitis PigmentosaUnited Kingdom, United States
-
Oslo University HospitalRecruitingRetinitis Pigmentosa | Retinitis Pigmentosa 11Norway
-
Jinnah Burn and Reconstructive Surgery Centre,...The Layton Rahmatullah Benevolent Trust (LRBT) Free Eye Hospital, Township... and other collaboratorsRecruitingRetinitis Pigmentosa (RP)Pakistan
-
AbbVieActive, not recruitingAdvanced Retinitis PigmentosaUnited States
-
jCyte, IncCalifornia Institute for Regenerative Medicine (CIRM)CompletedRetinitis Pigmentosa (RP)United States
-
Janssen Research & Development, LLCJanssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaBelgium, Canada, United States, Israel, United Kingdom, Spain, Denmark, France, Italy, Netherlands, Switzerland
-
Janssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaUnited States, United Kingdom
-
GenSight BiologicsRecruitingNon-syndromic Retinitis PigmentosaUnited States, France, United Kingdom
-
Janssen Research & Development, LLCJanssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaUnited States, Canada, Israel, United Kingdom, Spain, Denmark, France, Belgium, Italy, Netherlands, Switzerland
-
BiogenCompletedX-Linked Retinitis PigmentosaUnited States, United Kingdom
Clinical Trials on Navigation System for Users of a Visual Prosthesis
-
Istituto Ortopedico RizzoliCompleted
-
Alison GalbraithNational Institute on Aging (NIA); Massachusetts Institute of Technology; Harvard... and other collaboratorsCompletedno Specific Condition Targeted | Use of a Price Transparency ToolUnited States
-
Technische Universität DresdenCompleted
-
University Hospital, Strasbourg, FranceCompletedOtorhinolaryngologic DiseasesFrance
-
University Hospital, Strasbourg, FranceCompletedDysphagia | Swallowing Disorders | Laryngeal NeoplasmsFrance
-
Johns Hopkins Bloomberg School of Public HealthCompletedOpioid Use Disorder | Substance Use Disorders | Stigma, SocialUnited States
-
University Hospital, Strasbourg, FranceUnknown
-
Istanbul Physical Medicine Rehabilitation Training...CompletedNeuropathy | Ankylosing Spondylitis | Anti - TNF TherapyTurkey
-
University of Central ArkansasCompletedPelvic Floor Muscle WeaknessUnited States
-
Bezmialem Vakif UniversityCompletedAnalgesia | Anesthesia | Sedation | Airway Complication of AnesthesiaTurkey